At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a growing shift in how artificial intelligence (AI) is delivering value within pharmaceutical commercial and field medical functions. While AI adoption has become increasingly widespread, translating this into measurable business outcomes has remained a key challenge.
Sam Rolfe, sales director EMEA at Exeevo, emphasised that successful AI initiatives must go beyond experimentation and demonstrate clear, quantifiable impact. A major barrier to achieving this lies in fragmented data environments and the lack of alignment between people, processes, and technology, which continue to limit the effectiveness of AI-driven insights.
Go deeper with GlobalData
Exeevo’s “Ask-Nova” solution was presented as an example of how AI can be embedded directly into daily workflows to support field teams. By assisting with tasks such as meeting preparation, note-taking, and customer relationship management (CRM) data entry, the platform enables representatives to reduce administrative burden and focus more on high-value interactions with healthcare professionals.
According to Rolfe, AI-driven workflow tools can deliver measurable improvements, including reductions of up to 30–40% in time spent on administration tasks, and a return on investment (ROI) within six months. These gains not only improve operational efficiency but also contribute to enhanced data quality and stronger engagement outcomes.
